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individual N-of-1 trial, and modifies the CONSORT flow diagram to address the flow of a series of N-of-1 trials. The rationale, development
process, and CENT 2015 checklist and diagrams are reported in this document.  2015 The Authors. Published by Elsevier Inc. This is
an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
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by-nc/4.0/).1. Introduction
Although randomized controlled trials are the ideal for
establishing treatment efficacy, they have limitations
[1,2]. In particular, even the most rigorous and clearly re-
ported randomized controlled trial cannot predict if a given
intervention will be effective in a specific individual. For
this reason, N-of-1 trials have been placed, by some, on
the pinnacle of the evidence hierarchy for making decisions
about treatment benefits and harms [3,4]. They use key
methodological elements of group clinical trials to evaluate
treatment effectiveness in a single patient, for situations
that cannot always accommodate large-scale trials: rare dis-
eases, comorbid conditions, or in patients using concurrent
therapies.s article under the CC BY-NC license (http://creativecommons.org/licenses/
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conditionsdincluding mental and behavioral disorders and
diseases of the nervous, respiratory, circulatory, musculo-
skeletal, and digestive systems [5]dand are appropriate
for a range of interventions, pharmacologic, or nonpharma-
cologic, including complementary or alternative therapies.
However, N-of-1 trials are not applicable for all health con-
ditions or interventions. They are ideal for chronic stable
conditions and for therapies with a relatively quick onset
of action after initiation and quick termination of effect af-
ter discontinuation.
In an era that promotes patient-centered research,
comparative effectiveness, and personalized medicine,
N-of-1 trials allow clinicians and patients to evaluate health
interventions in a rigorous fashion and to re-evaluate
chronic therapies to ensure therapeutic effectiveness is still
achieved. N-of-1 trials are a unique tool to elicit patient
preferences and to facilitate shared decision making, hence
evidence-based medicine, in real clinical practice. In addi-
tion, N-of-1 trials may also be used to assess causality of
potential adverse effects. By reducing ineffective polyphar-
macy, N-of-1 trials may help promote patient safety.Fig. 1. Common single case designs. CENT is applicable to a subset of
the ‘‘withdrawal/reversal designs’’ category, which may or may not
include the use of randomization, designated by the red ‘‘N-of-1’’
box. (For interpretation of the references to color in this figure legend,
the reader is referred to the Web version of this article.) (adapted from
[21])2. N-of-1 methodology and reporting
N-of-1 trials provide a methodologically rigorous evalua-
tion of treatment effectiveness in a single individual at a time,
thereby helping to close the gap between evidence and prac-
tice. Unlike randomized controlled trials, which often exclude
patients with comorbid conditions or concurrent therapies,
N-of-1 trials allow a more flexible approach. Patients may
be included as long as their health and concurrent therapies
are stable during the period of evaluation; caution is neces-
sary if combining results of N-of-1 trials because of heteroge-
neity between patients. As in group crossover trials, the
potential for confounding by covariates is eliminated in
N-of-1 trials given that each patient serves as his or her
own control. The use of multiple crossovers in N-of-1 trials
also increases confidence in the reliability of the results.
A recent systematic reviewof100 trial reports indicates that
the reporting of N-of-1 trials is largely inadequate [5]. As an
example, 79% of reports included in the review did not indi-
cate that outcome was considered to be primary. Another
64% of reports did not comment on the presence or absence
of adverse events. If N-of-1 trials are to be useful, these and
other essential pieces of information must be included.
Among the first initiatives aiming to improve the complete-
ness of reporting of research studies was the CONSORT
guideline,whichfirst emerged in1996 [6] andhasbeen revised
twice,most recently in 2010 [7,8], to keep in linewith evolving
evidence and methodological standards for trials. Extensions
to the main CONSORT document have been developed to
address the reporting of variations in trial designs [9e11], in-
terventions [12e14], and data [15e17]. The CENT guideline
provides a set of items, modified from the CONSORT 2010guideline to facilitate complete reporting of N-of-1 trials.
The development ofCENT2015 is in linewith recent, interna-
tional efforts to improve the reporting of research overall [18].
For convenience, throughout this document, we refer to
treatments and patients, although we recognize that not all
interventions evaluated in N-of-1 trials are technically
treatments and that participants are not always patients.3. Terminology and scope of CENT
The single case experimental design, including N-of-1
trials, has a long history in the behavioral sciences
[19,20]. In the medical literature, the term ‘‘N-of-1 trial’’
is used to describe a prospectively planned, multiple cross-
over trial in a single individualdoften challenge-
withdrawal-challenge-withdrawal, also described as
‘‘ABAB’’ [20]. CENT restricts itself to this use of the term
‘‘N-of-1,’’ rather than all possible single case experimental
designs (Fig. 1), for which a separate reporting guideline is
under development [22]. Consisting of repeated units of
treatment comparisons (see Box 1), N-of-1 trials may
compare an active treatment against placebo, more than
one active treatment, or perhaps multiple doses of a single
treatment. The comparison depends on the question that is
being asked. Definitions of methodological terminology
specific to N-of-1 trials are provided in Box 1.
Because approximately 60% of N-of-1 trial publications
report on results from more than a single patient [5], the
CENT reporting guidelines have been designed to facilitate
the reporting of both a single N-of-1 trial and a prospec-
tively planned series of multiple N-of-1 trials. Readers
may also wish to use the checklist to facilitate the critical
appraisal of published N-of-1 trial reports for completeness
and transparency. This guidance is not intended to be
applied by those reporting systematic reviews in which
N-of-1 trials are included; future such guidance is planned.
4. Developing the CENT Statement
An international steering committee (D.G.A., Nick Bar-
rowman, C.B., G.G., D.M., J.N., M.S., R.T., and S.V.)
Box 1 Methodological terminology typical in
N-of-1 trial reports
N-of-1 trialdAn experimental clinical study
design to determine the effect of an intervention in
a single-study participant. CENT is intended to be
used to report repeated challenge-withdrawal (i.e.,
‘‘ABAB’’) trials, commonly used in medicine, in
which multiple crossovers between treatment(s) and
control (placebo, standard care, alternate treatment)
are continued for a prespecified amount of time or un-
til treatment effectiveness is determined. More than
two treatment alternatives may be compared with
each other or control (i.e., ‘‘ABCABC’’).
PerioddThe time during which a single treatment
(A or B) is administered. Period length is typically
determined a priori and may vary within a trial.
The order of periods within a pair or treatment block
may be randomized.
Block or pairdA repeated unit of a set number of
period in N-of-1 trials is referred to as a block, in
which the sequence of periods may or may not be ran-
domized (e.g., three repeating blocks of four periods
may look like ‘‘AABB BBAA ABAB’’). By conven-
tion, when the repeated unit contains only two periods
(e.g., three repeating pairs may look like ‘‘AB BA
BA’’), it is conventionally referred to as a pair.
SequencedMultiple pairs or blocks comprise an
entire sequence. The sequence is the consecutive set
of periods, which may or may not indicate size of
the repeated unit.
Washout perioddA period in which no interven-
tion is administered. A washout may be administered
between different treatment periods or may act as a
period in itself, as in a ‘‘reversal’’ design (to ‘‘wash
out’’ the effects of a treatment before it is
readministered).
Run-in perioddA prespecified duration of time
before a trial begins, during which trial treatments
may be initiated (e.g., to get to a stable therapeutic
dose), to determine potential patient compliance with
study regimens, or to allow for washout of a medica-
tion(s) a patient may have been taking before the
trial.
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methodology and reporting guideline development,
together with the project coordinator (L.S.), led the devel-
opment of CENT. Two members of the team are practising
physicians (S.V. and J.N.), and two others are members of
the CONSORT and EQUATOR (Enhanced Quality and
Transparency of Reporting) Network executive (D.G.A.
and D.M.). The EQUATOR Network is a group dedicatedto ‘‘improving the reliability and value of medical research
literature by promoting transparent and accurate reporting
of research studies’’ (www.equator-network.org). The
CENT Statement was developed in accordance with the
process developed by members of EQUATOR executive
group [23].4.1. Premeeting activities
To assess whether a reporting guideline for N-of-1 trials
was indeed warranted, members of the CENT group (C.B.,
M.S., L.S., and S.V.) undertook a systematic review to
assess the design and reporting of N-of-1 trials in the med-
ical literature [5]. This work confirmed the heterogeneity in
N-of-1 trials, and large inadequacies in their reporting, as
described previously.
Between February 2009 and April 2009, a modified Del-
phi process was carried out to seek consensus on a set of
potential reporting items (n 5 55) for N-of-1 trials. This
initial list was developed based on the characteristics of
published trials guided by our systematic review and report-
ing elements from the CONSORT 2010 checklist [7]. A
two-round survey was sent out to 56 international experts
of N-of-1 trialists, biostatisticians, clinical epidemiologists,
reporting guideline developers, biomedical journal editors,
and health research funders, of whom 75% and 62% re-
sponded in rounds 1 and 2, respectively. Participants were
asked to rank the importance of each potential checklist
item on a 1 to 10 scale. After both rounds of surveying,
items with a mean ranking of 5 were excluded from
further consideration on the CENT checklist. Items ranking
6 or for which there was a large discrepancy between par-
ticipants were carried forward for further discussion at the
CENT consensus meeting.4.2. CENT consensus meeting
In May 2009, a 2 day, in-person meeting was convened
in Banff, Canada, during which 23 experts in N-of-1 meth-
odology, guideline development, N-of-1 study funders, and
journal editors came together to further discuss and refine
proposed checklist items. Discussion at the meeting yielded
agreement on a set of essential concepts to be included in
the guidelines; nuances of wording were not discussed at
the meeting.4.3. Postmeeting activities
After the CENT meeting, wording and organization of
concepts into checklist items were carried out and refined
within the steering group and approved by meeting partici-
pants. A second round of circulation solicited feedback from
those invited to the meeting but unable to attend. A flow di-
agram subcommittee was formed (N.B.G., J.N., and D.R.Z.)
to lead development of the CENT flow diagrams.
Table 1. CENT 2015 checklista
Section/topic
CONSORT 2010 CENT 2015
No Item No Item
Title and abstract
1a Identification as a randomized trial in the
title
1a Identify as an ‘‘N-of-1 trial’’ in the title
For series: Identify as ‘‘a series of N-of-1
trials’’ in the title
1b Structured summary of trial design, methods,
results, and conclusions (for specific
guidance see CONSORT for abstracts)
1b For specific guidance, see CENT guidance for
abstracts (Table 2)
Introduction
Background and objectives 2a Scientific background and explanation of
rationale
2a.1
2a.2 Rationale for using N-of-1 approach
2b Specific objectives or hypotheses 2b
Methods
Trial design 3a Description of trial design (such as parallel,
factorial) including allocation ratio
3a Describe trial design, planned number of
periods, and duration of each period
(including run-in and washout, if
applicable)
In addition for series: Whether and how the
design was individualized to each
participant and explain the series design
3b Important changes to methods after trial start
(such as eligibility criteria), with reasons
3b
Participant(s) 4a Eligibility criteria for participants 4ab Diagnosis or disorder, diagnostic criteria,
comorbid conditions, and concurrent
therapies.
For series: Same as CONSORT item 4a
4b Settings and locations where the data were
collected
4bb
4c Whether the trial(s) represents a research
study and if so, whether institutional ethics
approval was obtained
Interventions 5 The interventions for each group with
sufficient details to allow replication,
including how and when they were actually
administered
5 The interventions for each period with
sufficient details to allow replication,
including how and when they were actually
administered
Outcomes 6a Completely defined prespecified primary and
secondary outcome measures, including
how and when they were assessed
6a.1
6a.2 Description and measurement properties
(validity and reliability) of outcome
assessment tools
6b Any changes to trial outcomes after the trial
commenced, with reasons
6b
Sample size 7a How sample size was determined 7a
7b When applicable, explanation of any interim
analyses and stopping guidelines
7b
Randomization:
Sequence generation 8a Method used to generate the random
allocation sequence
8a Whether the order of treatment periods was
randomized, with rationale, and method
used to generate allocation sequence
8b Type of randomization; details of any
restriction (such as blocking and block
size)
8b When applicable, type of randomization;
details of any restrictions (such as pairs,
blocking)
8c Full, intended sequence of periods
Allocation concealment
mechanism
9 Mechanism used to implement the random
allocation sequence (such as sequentially
numbered containers), describing any
steps taken to conceal the sequence until
interventions were assigned
9
Implementation 10 Who generated the random allocation
sequence, who enrolled participants, and
who assigned participants to interventions
10
(Continued )
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Table 1. Continued
Section/topic
CONSORT 2010 CENT 2015
No Item No Item
Blinding 11a If done, who was blinded after assignment to
interventions (e.g., participants, care
providers, those assessing outcomes) and
how
11a
11b If relevant, description of the similarity of
interventions
11b
Statistical methods 12a Statistical methods used to compare groups
for primary and secondary outcomes
12a Methods used to summarize data and
compare interventions for primary and
secondary outcomes
12b Methods for additional analyses, such as
subgroup analyses and adjusted analyses
12b For series: If done, methods of quantitative
synthesis of individual trial data, including
subgroup analyses, adjusted analyses, and
how heterogeneity between participants
was assessed (for specific guidance on
reporting syntheses of multiple trials,
please consult the PRISMA Statement)
12c Statistical methods used to account for
carryover effect, period effects, and
intrasubject correlation
Results
Participant flow (a diagram
is strongly recommended)
13a For each group, the numbers of participants
who were randomly assigned, received
intended treatment, and were analyzed for
the primary outcome
13a.1 Number and sequence of periods completed
and any changes from original plan with
reasons
13a.2 For series: The number of participants who
were enrolled, assigned to interventions,
and analyzed for the primary outcome
13b For each group, losses and exclusions after
randomization, together with reasons
13c For series: Losses or exclusions of
participants after treatment assignment,
with reasons, and period in which this
occurred, if applicable
Recruitment 14a Dates defining the periods of recruitment and
follow-up
14ab
14b Why the trial ended or was stopped 14b Whether any periods were stopped early and/
or whether trial was stopped early, with
reason(s).
Baseline data 15 A table showing baseline demographic and
clinical characteristics for each group
15b
Numbers analyzed 16 For each group, number of participants
(denominator) included in each analysis
and whether the analysis was by original
assigned groups
16 For each intervention, number of periods
analyzed.
In addition for series: If quantitative synthesis
was performed, number of trials for which
data were synthesized
Outcomes and estimation 17a For each primary and secondary outcome,
results for each group, and the estimated
effect size and its precision (such as 95%
confidence interval)
17a.1 For each primary and secondary outcome,
results for each period; an accompanying
figure displaying the trial data is
recommended.
17a.2 For each primary and secondary outcome, the
estimated effect size and its precision
(such as 95% confidence interval)
In addition for series: If quantitative synthesis
was performed, group estimates of effect
and precision for each primary and
secondary outcome
17b For binary outcomes, presentation of both
absolute and relative effect sizes is
recommended
17b
Ancillary analyses 18 Results of any other analyses performed,
including subgroup analyses and adjusted
analyses, distinguishing prespecified from
exploratory
18 Results of any other analyses performed,
including assessment of carryover effects,
period effects, intrasubject correlation
In addition for series: If done, results of
subgroup or sensitivity analyses
(Continued )
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Table 1. Continued
Section/topic
CONSORT 2010 CENT 2015
No Item No Item
Harms 19 All important harms or unintended effects in
each group (for specific guidance see
CONSORT for harms)
19 All harms or unintended effects for each
intervention (for specific guidance see
CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of
potential bias, imprecision, and, if
relevant, multiplicity of analyses
20
Generalizability 21 Generalizability (external validity,
applicability) of the trial findings
21
Interpretation 22 Interpretation consistent with results,
balancing benefits and harms, and
considering other relevant evidence
22
Other information
Registration 23 Registration number and name of trial
registry
23
Protocol 24 Where the full trial protocol can be accessed,
if available
24
Funding 25 Sources of funding and other support (such
as supply of drugs), role of funders
25
Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; CENT, CONSORT extension for N-of-1 trials; PRISMA, Preferred Report-
ing Items for Systematic reviews and Meta-Analyses.
CONSORT 2010 checklist items with modifications or additions for individual or series of N-of-1 trials; empty items in the CENT 2015 column
indicate no modification from the CONSORT 2010 item.
a It is strongly recommended that this checklist be read in conjunction with the CENT 2015 Explanation and Elaboration [24] for important
clarification on the items. The copyright for CENT (including checklist) is held by the CENT Group and is distributed under a Creative Commons
Attribution (CC-BY 4.0) license.
b Caution should be taken when reporting potentially identifying information pertaining to CENT items 4a, 4b, 14a, and 15.
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The final CENT 2015 checklist is an extension of 14
items of the 25 CONSORT 2010 (Table 1) and contains a
total of 44 subitems, some of which are modifications of
a standard CONSORT 2010 item and some of which are
in addition. For item 1b, pertaining to the abstract, recom-
mendations specific for N-of-1 trials are proposed in
Table 2. Because N-of-1 trials may be conducted for an in-
dividual or a series of individuals, where pertinent, the
checklist indicates specific items where different or addi-
tional information is required for series of N-of-1 trials.
The recommendations within CENT may require more
words or space than N-of-1 trialists are accustomed to.
Providing detailed descriptions for some trials will facili-
tate transparency and future reproducibility, in line with
emerging journal policies aimed at facilitating reproduc-
ibility [25].
We recognize that improved reporting must be balanced
against patient confidentiality in situations when the condi-
tion is rare. Authors must be mindful of this, and if there
is any doubt as to whether complete reporting could be iden-
tifying, they should seek consultation with their institutional
ethics board. This issue is of heightened importance in N-of-
1 trials of rare conditions or when the potential societal
stigma is high. Caution should be taken when reporting a
combination of identifying information pertaining to CENT
items 4a, 4b, 14a, and 15.6. CENT diagrams
Diagrams have been developed to help authors visually
depict both an individual participant’s progress through
an N-of-1 trial (Fig. 2, CENT trial pictorial) and the flow
of multiple participants through a series of trials (Fig. 3,
CENT flow diagram). Authors are encouraged in include
the relevant diagram(s) in their N-of-1 reports. Specific
guidance on the information that should be included in each
diagram is provided in the CENT Explanation and Elabora-
tion (E&E) document [24].7. CENT 2015 E&E document
Once the CENT checklist was drafted, the steering com-
mittee and members from the larger CENT group prepared
a rationale and examples of good reporting for the final set
of checklist items. These can be found in the CENT 2015
E&E document [24]. The principles addressed in this docu-
ment were largely derived from existing literature, the
CONSORT 2010 E&E document [8] where applicable,
and from discussions at the CENT meeting, which was re-
corded and summarized.
We strongly recommend that authors preparing N-of-1
trial reports and those charged with reviewing them use
the CENT 2015 checklist to guide or assess their reporting.
Authors are urged to read and use the CENT 2015 E&E
document together with the checklist, as it provides
Table 2. CENT abstract considerations (modifications or additions to CONSORT Statement for Abstracts)
Item CONSORT for abstracts Extension for N-of-1 designs
Title Identification of the study as randomized Identification of the study as an N-of-1 trial or series of
N-of-1 trials in the title
Authorsa Contact details for the corresponding author
Trial design Description of trial design (such as parallel, cluster,
noninferiority)
Description of trial design, number of periods, and
period duration
Methods:
Participant(s) Eligibility criteria for participants and the settings
where the data were collected
For individual trial, clinical condition under study
For series, eligibility criteria for participants
Interventions Interventions intended for each group Interventions intended for each period
Objective Specific objective or hypothesis
Outcome Clearly defined primary outcome for this report
Randomization How participants were allocated to interventions
Blinding (masking) Whether participant(s), care givers, and those assessing
the outcomes were blinded to group assignment
Results:
Numbers randomized Number of participants randomized to each group For individual N-of-1 trial, the number and sequence of
periods completed
For series, number of individual trials carried out
Recruitment Trial status Not applicable
Numbers analyzed Number of participants analyzed in each group For individual N-of-1 report, number of periods
analyzed for each intervention
For series, the number of participants analyzed
Outcome For the primary outcome, a result for each group and the
estimated effect size and its precision
Harms Important adverse events or side effects.
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register, if
applicable
Funding Source of funding
Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; CENT, CONSORT extension for N-of-1 trials.
a For conference abstracts.
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based rationale and guidance on how to report each item
[24].8. Postpublication activities
Postpublication activities are planned around CENT 2015,
including collecting feedback from the broader scientific com-
munity on the CENT initiative and specific checklist items.WeFig. 2. N-of-1 trial pictorial; suggested visual representation of data
from an individual N-of-1 trial.also plan to seek endorsement frommedical journals known to
publish N-of-1 trials (see below). The CENT 2015 checklist,
statement, and E&E documents are available through the
CONSORTWeb site (www.consort-statement.org) and acces-
sible through the Enhancing the Quality and Transparency of
Health Research (EQUATOR) Network library of reporting
guidelines (http://www.equator-network.org/resource-centre/
library-of-health-research-reporting/).8.1. Endorsement
The CONSORT Statement is likely the best known report-
ing guideline. It has been well received by several scientific
organizations (including the International Committee of Med-
ical Journal Editors, Committee on Publication Ethics, and
World Association of Medical Editors) and many biomedical
journals, over 600 of which currently endorse CONSORT.
Endorsement is typically demonstrated by way of an editorial
statement in a journal’s ‘‘Instructions to authors’’ section,
supporting the use of one or more reporting guidelines. After
this model, we plan to seek endorsement from journals that
publish N-of-1 trials and work with these journals to ensure
author adherence to reporting CENT 2015 items. To help
journals ensure optimal use of the CENT 2015 by authors,
we propose the following wording:
Fig. 3. CENT flow diagram; suggested representation of the flow of
participants in a series of N-of-1 trials.
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list as a condition of submission of reports of individual N-
of-1 trials or a series of N-of-1 trials. We recommend that
although completing this form, you consider amending
your manuscript to ensure your article, at a minimum, ad-
dresses each item listed on the CENT 2015 checklist. Tak-
ing the time to ensure your manuscript meets these basic
reporting requirements will greatly improve your manu-
script, potentially enhancing its chances for eventual
publication.’’8.2. Registering N-of-1 trials
N-of-1 trials can be prospectively registered in existing
trial registries (albeit with some modifications). Eventually,
we plan to work with clinicaltrials.gov and all the primary
registries within the WHO Registry Network (www.who.
int/ictrp/network/primary/en/index.html), in accordance
with the International Clinical Trials Registry Platform, to
enable a broader audience to more easily register their N-
of-1 trials. This will help to increase the transparency of
N-of-1 trial reporting and facilitate appraisal of trial reports
for potential biases (selective reporting). Although it is
possible to register N-of-1 trials in existing registries, few
published N-of-1 trials have been registered or indicate
being registered in their published report.8.3. Evaluation
As with other reporting guidelines, the impact of CENT
can be evaluated by comparing the completeness ofreporting of checklist items between N-of-1 trial reports
published in journals endorsing and not endorsing the
CENT checklist as well as before vs. after endorsement
in endorsing journals. This approach reflects methods pre-
viously used to evaluate CONSORT and other reporting
guidelines [26,27].9. Conclusion
N-of-1 trials offer a pragmatic approach to evidence-
based clinical practice. Rather than forcing patients into
an all or none fit with a rigid parallel group-based trial
protocol, N-of-1 trials can be flexible and adapt around
the individual to help assess treatment effectiveness under
real-world circumstances. They facilitate shared decision
making between patients and practitioners, thereby
bringing evidence-based medicine into real clinical prac-
tice. Although N-of-1 trials can be flexible enough for clin-
ical use, they can also be standardized in this research,
which may allow outcomes to be combined for population
estimates. By improving the clarity of N-of-1 trial report-
ing, the CENT 2015 guidelines offer an opportunity to
improve the interpretation and usefulness of N-of-1 trials.
The CENT 2015 guideline is primarily intended to be
used by authors and reviewers who report and assess N-
of-1 trials, respectively. It may also be helpful earlier in
the research process as researchers design protocols for
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